ARCHIVES

Advisors Reaffirm Survival As Standard For full FDA Approval Of Cancer Drugs

This article is from The Cancer Letter archive.

Vol. 25 No. 24 | June 16, 1999

Download PDF Visit The Full Archive

Related Articles

Organ Systems Program Defenders Go On Offense At NCAB Committee Meeting

December 11, 1987

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

April 25, 2014

An Alliance of NSABP-RTOG And GOG?

March 25, 2011

ASCO Writes A New Mission Statement Placing Emphasis On Helping Patients

May 21, 1999

Funding opportunities listed.

March 26, 2004

FDA Approves Silicone Gel Breast Implants, Requires 10 Years Of Patient Follow-Up

November 24, 2006